The FDA Is Opening the Door. CMS Is Narrowing the Window. Here's What That Means for Your Market.
Two regulatory moves. Opposite directions. Same underlying pressure.
In January, the FDA re-wrote its guidance on AI-enabled clinical decision support software — quietly expanding the path to market for a broad class of digital health tools that previously faced device classification. No premarket clearance required, no 510(k) submission, no PMA. If your tool supports a clinician's judgment rather than replacing it, and the logic is transparent and reviewable, you may now have a clear lane to market that didn't exist before.
Meanwhile, CMS has spent the past three months holding firm on its December 2024 restructuring of skin substitute and cellular tissue product reimbursement — and this week got explicit legal backing from value-based care organizations in the CAMPs Initiative lawsuit. The government's position is hardening, not softening.
Two agencies. Two signals. One market.
If you work in wound care, limb salvage, or foot and ankle, both of these moves affect how you operate — and how your market is going to look in 24 months. This Take breaks them down individually, connects them, and tells you what to watch for.
Part One: The FDA AI Guidance Shift
What Actually Changed
On January 6, 2026, FDA Commissioner Makary released updated guidance on Clinical Decision Support Software — the most significant digital health regulatory shift since the 21st Century Cures Act created the original non-device CDS framework in 2016.
The headline change is deceptively simple. Under the prior 2022 guidance, any software that delivered a single clinical recommendation was automatically treated as a regulated medical device — triggering 510(k) or De Novo requirements, quality system obligations, and premarket review. The logic was that a single-output tool created automation bias risk: the clinician gets one answer and anchors on it.
The 2026 guidance rejects that framing. A single, clinically appropriate recommendation can now qualify as non-device CDS — exempt from premarket review — if the software meets three conditions: it supports rather than replaces clinical judgment, the clinician can independently review and understand the basis for the recommendation, and the tool is not being used in time-critical or autonomous clinical decision-making contexts.
That third condition matters. Tools used in time-sensitive, high-acuity situations — sepsis alerts, acute cardiac events, emergency triage — remain regulated. But tools used in structured wound assessment, care planning, treatment selection, and follow-up monitoring almost universally fall outside that high-acuity definition. Which means the practical expansion for wound care AI is significant.
What This Means for the Wound Care Market
Wound documentation and imaging AI has been in a regulatory gray zone for years. The question of whether an AI tool that analyzes a wound image and recommends a treatment protocol is a non-device CDS or a regulated medical device has been genuinely uncertain — and that uncertainty has slowed investment, delayed product development, and kept several promising platforms in legal review rather than clinical deployment.
The January 2026 guidance resolves much of that uncertainty in the non-device direction. A platform that analyzes wound photography and produces a care recommendation the clinician can review, override, and document — and where the algorithm's logic is transparent — can now reach market without FDA premarket clearance. That is a material change for the competitive landscape.
Companies in wound imaging and AI-assisted documentation — including Spectral AI's DeepView platform, MolecuLightDx's bacterial fluorescence imaging, and a growing pipeline of wound EMR-integrated AI tools — are all building in spaces directly affected by this shift. The path to deployment in wound care centers, home health settings, and outpatient clinics is shorter today than it was twelve months ago.
The infection detection category — exemplified by NanoBioFab's RAPID-iNose nanosensor platform — sits in similar territory. A wearable that continuously monitors pathogen gas signatures and alerts a clinician to emerging infection before clinical signs appear is exactly the kind of single-recommendation, clinician-reviewable tool this guidance is designed to accommodate.
For companies in the wound imaging and remote monitoring space, the question has shifted from "can we get this cleared?" to "can we get this into clinical workflows?" — which is a fundamentally different and more solvable problem.
What the Guidance Does Not Change
Two important limitations. First, the non-device CDS pathway requires that clinicians can independently review and understand the basis for the tool's recommendations. Black-box AI — tools where the algorithm's logic is opaque or proprietary to the point of being unverifiable — does not qualify. This has direct implications for wound care AI developers: explainability is no longer a nice-to-have feature. It is a regulatory requirement for staying outside device classification.
Second, the FDA has explicitly stated that more AI-specific guidance is coming — including a new risk-based framework and a reissued Device Software Functions guidance. The current expansion is not the final word. Companies building on the January 2026 guidance should be monitoring the CDRH guidance agenda closely, because the regulatory ground is still moving.
Part Two: The CMS Skin Substitute Restructuring
Where the Rule Stands
In December 2024, CMS issued commentary that fundamentally restructured how cellular and tissue-based products — skin substitutes, amniotic membranes, and related CTPs — are reimbursed under Medicare Part B. The change moved high-cost skin substitute products from an add-on reimbursement model, where they were billed separately at significant margins above cost, into a consolidated payment framework that dramatically reduced per-application reimbursement for many products.
The practical effect was immediate. Organogenesis guided FY2026 revenue at $350–420M — down 25–38% from a record 2025. Clinician utilization froze in Q1 2026 as providers and practices tried to understand which products remained financially viable under the new structure. The BTK WoundCare Fund has reflected that uncertainty week over week.
The industry response was the CAMPs Initiative lawsuit, filed in the U.S. District Court for the Northern District of Texas. The plaintiffs — skin substitute manufacturers and distributors — are seeking to invalidate the CMS rule and restore the prior payment framework, arguing CMS exceeded its statutory authority and failed to engage in proper rulemaking.
The Amicus Brief and What It Signals
On March 18, value-based care organizations — including ACOs and physicians participating in value-based payment models — filed an amicus brief supporting the government's motion to dismiss. The brief, filed by Arnall Golden Gregory on behalf of these organizations, makes two arguments that matter.
First, it argues that the prior reimbursement structure created financial incentives that drove escalating Medicare expenditures — and that those incentives contributed to fraud, waste, and abuse in the CTP category. Second, it argues that CMS acted within its statutory authority and engaged in reasoned decision-making.
The significance of this filing is not primarily legal — it is political and coalitional. The CMS restructuring now has explicit, on-the-record support from the value-based care community. ACOs and value-based providers have standing and credibility in Medicare policy debates that skin substitute manufacturers do not. The coalition defending this rule is broader than just CMS.
For companies that were tracking the litigation as a likely path to full rule reversal, this brief is a signal to update that assumption. A full rollback is becoming less likely, not more. A negotiated modification — narrowing the payment reduction or creating product-specific carve-outs — remains possible, but the current rule is hardening as the legal baseline.
What the Restructuring Actually Filters
The BTK framing from February still holds: CMS didn't break the skin substitute market. It filtered it.
The products that were most exposed to the December 2024 restructuring were those where the reimbursement margin — not the clinical outcome — was the primary driver of utilization. High-cost amniotic membrane products applied in high-volume, low-documentation settings were the target. Products with documented clinical outcomes, appropriate patient selection, and cost-effectiveness data are in a materially different position.
The companies that will recover are not the ones waiting for the rule to be reversed. They are the ones building the clinical evidence, outcome documentation, and payer engagement strategies that justify reimbursement under a tighter standard. That work takes 12 to 24 months to execute. The companies that started it in January are already ahead.
Part Three: What These Two Signals Mean Together
Here is the frame that connects them.
CMS is raising the evidentiary bar for reimbursement. The December 2024 restructuring is the first move in what is likely to be a broader trend toward outcome-linked, evidence-justified reimbursement for advanced wound care products. The era of high-margin skin substitute reimbursement without rigorous outcome documentation is ending.
The FDA is lowering the barrier to market for clinical decision support tools. The January 2026 guidance creates a wider non-device pathway for wound imaging, infection detection, care planning software, and remote monitoring tools that support clinical judgment with transparent, reviewable logic.
Read together, the regulatory environment is being reshaped in a specific direction: toward tools that generate outcome data, documentation, and clinical evidence — and away from products and practices that generate margin without accountability.
The companies that recognize this as a coherent direction — not two unrelated regulatory moves — are the ones that will be positioned to win over the next 24 months.
What It Means for Each Segment
If you're a clinician: The AI tools coming to market under the new FDA guidance are going to be documentation and decision support tools first — wound imaging, infection risk scoring, care plan generation, outcome tracking. These are not tools that replace clinical judgment. They are tools that make clinical judgment more defensible and documentable under a CMS environment that will increasingly demand evidence before reimbursement. Early adoption of these tools is not just a workflow efficiency play. It is a reimbursement protection play.
If you're in commercial or BD: The skin substitute restructuring is a category reset, not a category collapse. The window to compete is now about clinical evidence and payer strategy, not product margin. If your company sells a CTP product, the commercial conversation has to shift from reimbursement mechanics to outcome documentation. If you're selling wound AI tools, the FDA guidance shift means your path to clinical deployment is faster — but your sales cycle now involves educating on the regulatory landscape, not just the product. The clinicians and systems that understand the new framework will adopt faster. The ones that don't will wait.
If you're an investor: Two investable theses are emerging from this environment. The first is wound care AI platforms with explainable algorithms, clinical workflow integration, and outcome data — the combination that qualifies for non-device CDS under the new FDA guidance and generates the documentation CMS will increasingly require. The second is CTP and advanced wound care companies with genuine clinical evidence, appropriate patient selection protocols, and outcomes data that survives scrutiny under tighter reimbursement standards. Both of these are 18 to 36-month theses. The near-term volatility in names like Organogenesis reflects the transition period. The durable position is in companies building for the world that exists on the other side of that transition.
Looking Forward
Three things to watch over the next 12 months as these regulatory moves work through the market.
The FDA AI framework update is coming. Commissioner Makary has explicitly previewed a new risk-based AI regulatory framework and a reissued Device Software Functions guidance. When that framework drops, it will either confirm and extend the January 2026 expansion or introduce new conditions. Companies building on the current guidance should be monitoring the CDRH guidance agenda and engaging in the comment process.
The CAMPs Initiative litigation will reach a decision point. The Northern District of Texas will rule on the government's motion to dismiss. If the court dismisses, the CMS restructuring survives intact and the industry has to adapt. If the court denies dismissal, the litigation moves to the merits — and the policy uncertainty extends. Either outcome has a direct read-through to skin substitute company valuations.
Outcome documentation becomes a competitive moat. As CMS moves toward tighter reimbursement standards, the companies that have invested in real-world evidence generation — prospective outcome tracking, registry participation, health economics data — will be able to defend their reimbursement position in ways that companies without that data cannot. This is a slow-moving advantage that compounds over time. The companies starting that work now will have a two-to-three-year lead by 2028.
The FDA is clearing the runway for wound care AI. CMS is raising the bar for wound care reimbursement. The companies that use AI to clear that bar will own the next cycle.
Know someone in wound care, limb salvage, or foot and ankle who'd find this useful? Forward it to them. The best signal travels by word of mouth.
New? Subscribe Here
Catch last Friday's full Market Signal → [link to previous issue]
See you Friday. — Scott